This report presents information about the quickly emerging worldwide epigenetics market. This important life science market includes key product areas that will have a powerful impact on current and future healthcare. This broad and high-level report takes a business focus and analyzes epigenetics markets such life science tools and technologies, diagnostics and therapeutics
We all know about the human genome and our DNA. Its special code defines the structure of who we are, our potential health and our characteristics that we pass on to our children. Epigenetics represents the second code of life that signals to the DNA whether and when genes are activated or silenced. The genome is like the musical instrument; the epigenome is like the music.
The study discusses the market for life science tools and technologies that enable epigenetics R&D. The report discusses key equipment and consumables including microarray, next-generation sequencing, PCR and other platforms. Topics such as microRNA and human stem cells are lightly covered. The report highlights some of main government grant initiatives such as the NIH’s Roadmap Epigenomics Program initiatives, the EU’s Epigenetic Network of Excellence and others. The research covers subjects including important epigenetic factors including DNA methylation, histone modifications and other potential biomarkers.
The report discusses epigenetic commercial diagnostics and therapeutics that will foster personalized medicine. This research examines the current epigenetic therapeutics on the market and the drugs in the clinical pipeline.
This study discusses the interesting topics with key findings. The data estimates that the worldwide epigenetics product market will reach $1.7 billion in 2009, with a growth rate. The report reviews the activities of 35 companies. This report uses 39 figures and tables to illustrate the findings. This study features many convenient tables that help the reader scan the details of key trends, market segmentation, forecast, M&As, alliances, grant funding, patents and the like.
(0 items)
